February 2013 Editorial Line-up
|
PEER-REVIEWED
Increased Throughput and Reduced Operator Cost with Automated Concentration and Diafiltration of Multiple siRNA Samples
Rebecca Arvary, Deborah R. Cohen, Steven Vaughan, Catherine Blake
The use of small interfering RNA (siRNA) oligonucleotides for post-transcriptional gene silencing has proven to be an effective and powerful tool in the discovery of gene function. A team of scientists from GE Healthcare (GEHC) collaborated with Merck scientists with the project objective to transfer a conventional manual concentration/diafiltration process for siRNA production using five filtration systems to an optimized, automated process using two ÄKTAcrossflow filtration platforms. |
Navigating Emerging Markets—Eastern Europe
Jill E. Sackman, a senior consultant at Numerof & Associates, Inc., provides a look at manufacturing within global markets. This month’s article takes a look the Eastern European market. |
|
Value Added Opportunities
Product/Service Showcase
Bonus Distribution
• CASSS Bioassays
• EBD BIO Europe Spring
• IBC Biopharmaceutical
Development Production Week
Advertising Reservations Close:
January 11, 2013
Material Close: January 17, 2013 |
|
|
|
BiopharmInternational.com features an easy-to-use navigation with content available by targeted category, keyword search, or by issue. Enjoy extensive visibility of the site that reaches the universe of leading biotech companies and pharmaceutical companies with a biotech focus.
| PLUS, advertise in: |
| |
| • |
Science and Business e-Bulletin- Now Weekly |
| • |
E-Application Note Alert |
| • |
Whitepaper e-Library |
| • |
E-Solution broadcasts |
| • |
Digital Magazine |
| • |
Exclusively Sponsored Webcasts |
|
|
|
Special Focus: Vaccine Development and
Manufacture |
Guest Edit: Why Life Sciences Companies Don’t Seem to “Like” Social Media
Aaron Davidson, Baker Botts
Why is it that in 2013, so many life sciences companies avoid social media while most other industries embrace it?
|
Focus Section On: Vaccine Development and Manufacture
Cobra biologics will discuss the challenges associated with viral vaccine manufacture, and PDA will provide an update on the A-vax Quality-by-Design case study.
|
Assessing Development Needs for Biobetters and Biosimilars
Christina Satterwhite, Director, Laboratory Sciences, Preclinical Services, Charles River Laboratories
During the past 30 years, biotherapeutics have emerged as targeted drugs for indications, such as cancer, autoimmune disease, and hormone/enzyme disorders. Due to their specificity and generally reduced toxicity profiles, biotherapeutics have gained market share from classic small-molecule therapeutics. With many approved biotherapeutics coming off patent in the next several years, a new market for biologic products such as biosimilars and biobetters/biosuperiors is gaining ground. |
Boot Camp: Business Guide
In our monthly series with NIBRT, Michael Lacey provides an overview of biopharmaceutical facility design and operation. |
|
| • |
From the Editor |
| • |
Global News: Report from Latin America |
| • |
Regulatory Beat |
| • |
European Beat |
| • |
Dispoables Advisor |
| • |
Perspectives on Outsourcing |
| • |
Manufacturing Best Practices |
| • |
Product Spotlight & New Technology Showcase |
| • |
The Word |
|
|
